Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: The Company applies artificial intelligence (AI) to oncology drug discovery using a proprietary biobank of 150,000+ tumor samples (Pittsburgh segment) and previously produced the STREAMWAY® medical fluid disposal system (Eagan segment).
Recent Structural Changes: The Birmingham operating segment was discontinued in Q3 2024. The Eagan segment assets were sold to DeRoyal Industries, Inc. on March 14, 2025, leaving the Company focused solely on its AI-driven drug discovery business.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Revenue | $1,623,817 | $1,627,697 |
| Net Loss | $(12,664,388) | $(13,983,967) |
| Gross Profit Margin | 49% | 64% |
| Cash and Cash Equivalents | $734,673 | $8,728,660 |
| Operating Cash Flow (Continuing) | $(10,974,568) | $(11,784,070) |
| Accumulated Deficit | $(180,426,271) | $(167,761,883) |
| Short-Term Obligations | $3,593,401 | $3,951,031 |
Material Changes vs. Prior Period
- Revenue Stability with Margin Compression: Total revenue remained flat year-over-year ($1.62M), but gross margin declined from 64% to 49%. This was driven by a shift in sales mix toward the lower-margin Eagan segment (STREAMWAY systems) and a decrease in high-margin contracted services from the Pittsburgh segment.
- Expense Reduction: General and administrative expenses decreased by $961,025 (11.5%) primarily due to reduced headcount and lower severance costs compared to 2023.
- Discontinued Operations: The Birmingham laboratory segment was classified as discontinued operations in Q3 2024, resulting in a loss from discontinued operations of $1.8M for 2024.
- Liquidity Decline: Cash balances decreased by approximately $8.0M year-over-year due to significant negative operating cash flows, despite financing activities providing $3.9M in 2024.
Guidance, Outlook, and Risks
Going Concern Warning
Management has raised substantial doubt about the Company's ability to continue as a going concern. With only $734,673 in cash and short-term obligations of $3.6M, the Company requires significant additional financing to sustain operations beyond one year.
Strategic Transactions
- Renovaro Merger: On Jan 1, 2025, the Company entered a binding LOI to be acquired by Renovaro, Inc. in exchange for preferred stock. The deal is subject to Renovaro raising $15M and shareholder approval. If the deal fails but Renovaro funds the Company, Renovaro receives a royalty-free license to the biobank.
- Eagan Divestiture: Sold the STREAMWAY business to DeRoyal for $625,000 cash plus assumption of liabilities. This eliminates 95% of the Company's 2024 revenue stream, necessitating a pivot to the AI drug discovery model.
- Recent Financing: Raised $545k in a Feb 2025 registered direct offering and $1.3M in March 2025 warrant exercises.
Key Risks
- Delisting Risk: Received notice of non-compliance with Nasdaq minimum stockholders' equity requirements ($2.5M); submitted a plan based on the Renovaro merger to regain compliance.
- Regulatory: Potential FDA regulation of Laboratory Developed Tests (LDTs) could increase costs and delay commercialization.
- Technology: Reliance on AI predictions which are novel and unproven at scale; risk of algorithmic bias or regulatory changes.
Investor Verification Checklist
- Merger Viability: Verify the status of the Renovaro merger, specifically the $15M fundraising condition and shareholder approval timeline (extended to March 31, 2025).
- Liquidity Runway: Assess the sufficiency of the $734k cash balance against the $3.6M in short-term obligations and the timeline for the next financing round.
- Revenue Transition: Confirm the Company's ability to generate revenue from the Pittsburgh AI segment to replace the 95% of revenue lost from the Eagan divestiture.
- Nasdaq Compliance: Monitor the Company's progress in meeting Nasdaq equity requirements to avoid delisting.
- Warrant Overhang: Review the impact of 2.75M outstanding warrants (weighted avg exercise price $8.92) on future dilution.